COUR Pharmaceuticals has announced a strategic collaboration and licensing agreement with Genentech, a subsidiary of Roche (RHHBY, Financial), to jointly develop and commercialize COUR's proprietary tolerogenic nanoparticle therapy for autoimmune diseases.
Under the agreement, COUR will receive an upfront payment of $40 million along with near-term milestone payments. The company is also eligible for over $900 million in development, commercialization, and sales milestone payments. COUR will manage early clinical development and technology transfer, while Genentech will handle clinical development, regulatory submissions, and commercialization.
Currently, COUR is conducting a Phase 1b/2a clinical trial for myasthenia gravis and advancing a candidate drug for type 1 diabetes.
